Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.
PLoS One
; 7(6): e38150, 2012.
Article
em En
| MEDLINE
| ID: mdl-22761669
ABSTRACT
AIM:
To determine the pharmacogenetics of platinum-based chemotherapy in Non Small Cell Lung Cancer (NSCLC) patients.METHODS:
Publications were selected from PubMed, Cochrane Library and ISI Web of Knowledge. A meta-analysis was conducted to determine the association between genetic polymorphisms and platinum-based chemotherapy by checking odds ratio (OR) and 95% confidence interval (CI).RESULTS:
Data were extracted from 24 publications, which included 11 polymorphisms in 8 genes for meta-analysis. MDR1 C3435T (OR = 1.97, 95% CI 1.11-3.50, P = 0.02), G2677A/T (OR = 2.61, 95% CI 1.44-4.74, P = 0.002) and GSTP1 A313G (OR = 0.32, 95% CI 0.17-0.58, P = 0.0002) were significantly correlated with platinum-based chemotherapy in Asian NSCLC patients.CONCLUSION:
Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Platina
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Biomarcadores Tumorais
/
Carcinoma Pulmonar de Células não Pequenas
/
Polimorfismo de Nucleotídeo Único
/
Neoplasias Pulmonares
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article